The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

Forte Biosciences (FBRX) stock soared on Monday after the clinical-stage biopharmaceutical company announced results from a Phase 1b trial of FB102. This is the company’s lead program designed to ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.

ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues.

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager Provided by GlobeNewswire Apr 27, 2025, 11:00:00 AM ...